Clinical Trial Update: "Palivizumab Therapy for RSV-bronchiolitis" [Phase 3]

View source ↗

Summary

Phase 3 study of palivizumab for respiratory syncytial virus bronchiolitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Due to Respiratory Syncytial Virus

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: Respiratory Syncytial Virus-bronchiolitis | Phase 3 | Status: COMPLETED